Autolus Therapeutics (AUTL) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Autolus Therapeutics is the larger company by market cap ($481.8 million vs $408.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | EIKN |
|---|---|---|
| Share price | $1.81 | $7.54 |
| Market cap | $481.75M | $408.40M |
| 1-day change | +1.12% | +0.40% |
| YTD return | -9.05% | — |
| 1-year return | +21.48% | — |
| 5-year return | -70.52% | — |
| EPS (TTM) | $-1.06 | $-8.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $17.40 |
| 52-week low | $1.18 | $7.02 |
| Distance from 52-week high | -29.84% | -56.67% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +382.32% | +226.26% |
| Average volume | 2.10M | 485.89K |
| Shares outstanding | 266.16M | 54.17M |
| Employees | 752 | 384 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Healthcare · Biotechnology · 752 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Healthcare · Biotechnology · 384 employees
AUTL vs EIKN FAQ
Which is bigger, Autolus Therapeutics or Eikon Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $408.40M for Eikon Therapeutics (EIKN).
Are Autolus Therapeutics and Eikon Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.